IMCL
Imclone Systems, Inc
Biopharmaceutical company focused on oncology research and the development of the cancer drug Erbitux; acquired by Eli Lilly in 2008
CUSIP: 45245W109HealthcareUS1 holder
Total Value
$412.63M
Total Shares
11.67M
Net Share Change
0
Activity
No changes
Investor
Value
Shares
Weight
Change
